The global kidney cancer therapeutics & diagnostics market size was estimated to be USD 5.07 billion in 2023 and is expected to reach at USD 11.09 billion by 2034 with a CAGR of 7.38% during the forecast period 2024-2034. Growing prevalence of kidney cancer, rising research & development expenditures by market players, surge in product launches by the key market players, increasing funding for kidney cancer research, growing cases of renal cell carcinoma, rising demand for early diagnosis of kidney cancer, and increasing focus on development of novel therapy for kidney cancer are some of the key factors boosting the market growth.
Increasing focus on development of novel therapy for kidney cancer is predicted to boost the market growth during the forecast period. The diagnosis and treatment of kidney cancer include the use of therapies and diagnostics for renal cell carcinoma (RCC), Wilms tumors, transitional cell cancer, renal sarcoma, multilocular cystic RCC, medullary carcinoma, benign kidney tumors, and mucinous tubular and spindle cell carcinoma. Thus, there is a growing need for innovative therapies as kidney cancer incidence rises. For instance, in October 2022, Health Canada has granted approval for KEYTRUDA (pembrolizumab) to be used on its own in the adjuvant treatment of adults who have undergone nephrectomy or both nephrectomy and removal of metastatic growths, and who have intermediate-high or high risk of renal cell carcinoma (RCC) recurrence.
By cancer type, clear cell renal cell carcinoma was the highest revenue-grossing segment in the global kidney cancer therapeutics & diagnostics market in 2023 owing to rising prevalence of renal disorders, increasing adoption of various techniques in the diagnosis of ccRCC cancer, surge in research & development activity, and growing approvals by regulatory bodies. For instance, in November 2022, Aravive, Inc.'s primary initiative, batiraxcept, has been awarded Fast Track Designation by the U.S. FDA for patients dealing with advanced or metastatic clear cell renal cell carcinoma (ccRCC). This designation applies to cases where patients have experienced progression after receiving one or two earlier rounds of systemic treatment, encompassing both immune-oncology (IO) and vascular endothelial growth factor (VEGF) therapies. Additionally, urothelial carcinoma/transitional cell carcinoma is predicted to grow at fastest CAGR during the forecast period owing to the increasing cases of urothelial carcinoma, growing demand for chemotherapy, surge in research for the development of new drugs, and rising drug approvals by regulatory bodies.
By component, drugs was the highest revenue-grossing segment in the global kidney cancer therapeutics & diagnostics market in 2023 owing to growing prevalence of renal disorders, increasing need for novel treatments for the treatment of cancer and rising approvals by regulatory bodies. For instance, in August 2022, Celltrion Healthcare's Vegzelma (CT-P16) has received approval from the European Commission (EC) for treating metastatic renal cell carcinoma and other types of malignancies. Additionally, diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of kidney disorders, growing research & development activities, and increasing demand for early disease diagnosis.
By end-user, hospitals was the highest revenue-grossing segment in the global kidney cancer therapeutics & diagnostics market in 2023 owing to surge in number of people suffering from kidney disorders, rising healthcare infrastructure, and surge in introduction of innovative drugs. Additionally, pharmaceutical labs is predicted to grow at fastest CAGR during the forecast period owing to the increasing focus on development of advanced diagnostic techniques, growing research & development activities, and rising funding by major market players. For instance, in September 2022, The Department of Defense's Kidney Cancer Research Program has granted Weill Cornell Medicine $1 million over three years for research investigating the function of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of kidney cancer, rising product launches by the key market players, growing research & development expenditures by pharmaceutical companies, and increasing funding for research. For instance, in April 2023, The FY23 Defense Appropriations Act allocates funds for the Kidney Cancer Research Program (KCRP), specifically to back high-quality scientific research focused on kidney cancer. The entity responsible for overseeing the forthcoming funding opportunities is the CDMRP, housed within the U.S. Army Medical Research and Development Command (USAMRDC). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising incidences of kidney cancer, growing geriatric population, increasing awareness regarding cancer, surge in research & development expenditure by pharmaceutical companies, rising launch of novel drugs for the treatment of kidney cancer, and growing initiatives by major market players. For instance, in March 2023, Telix has reported further favorable findings from its concluded pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with clear cell renal cell carcinoma (ccRCC).
Increasing focus on development of novel therapy for kidney cancer is predicted to boost the market growth during the forecast period. The diagnosis and treatment of kidney cancer include the use of therapies and diagnostics for renal cell carcinoma (RCC), Wilms tumors, transitional cell cancer, renal sarcoma, multilocular cystic RCC, medullary carcinoma, benign kidney tumors, and mucinous tubular and spindle cell carcinoma. Thus, there is a growing need for innovative therapies as kidney cancer incidence rises. For instance, in October 2022, Health Canada has granted approval for KEYTRUDA (pembrolizumab) to be used on its own in the adjuvant treatment of adults who have undergone nephrectomy or both nephrectomy and removal of metastatic growths, and who have intermediate-high or high risk of renal cell carcinoma (RCC) recurrence.
By cancer type, clear cell renal cell carcinoma was the highest revenue-grossing segment in the global kidney cancer therapeutics & diagnostics market in 2023 owing to rising prevalence of renal disorders, increasing adoption of various techniques in the diagnosis of ccRCC cancer, surge in research & development activity, and growing approvals by regulatory bodies. For instance, in November 2022, Aravive, Inc.'s primary initiative, batiraxcept, has been awarded Fast Track Designation by the U.S. FDA for patients dealing with advanced or metastatic clear cell renal cell carcinoma (ccRCC). This designation applies to cases where patients have experienced progression after receiving one or two earlier rounds of systemic treatment, encompassing both immune-oncology (IO) and vascular endothelial growth factor (VEGF) therapies. Additionally, urothelial carcinoma/transitional cell carcinoma is predicted to grow at fastest CAGR during the forecast period owing to the increasing cases of urothelial carcinoma, growing demand for chemotherapy, surge in research for the development of new drugs, and rising drug approvals by regulatory bodies.
By component, drugs was the highest revenue-grossing segment in the global kidney cancer therapeutics & diagnostics market in 2023 owing to growing prevalence of renal disorders, increasing need for novel treatments for the treatment of cancer and rising approvals by regulatory bodies. For instance, in August 2022, Celltrion Healthcare's Vegzelma (CT-P16) has received approval from the European Commission (EC) for treating metastatic renal cell carcinoma and other types of malignancies. Additionally, diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of kidney disorders, growing research & development activities, and increasing demand for early disease diagnosis.
By end-user, hospitals was the highest revenue-grossing segment in the global kidney cancer therapeutics & diagnostics market in 2023 owing to surge in number of people suffering from kidney disorders, rising healthcare infrastructure, and surge in introduction of innovative drugs. Additionally, pharmaceutical labs is predicted to grow at fastest CAGR during the forecast period owing to the increasing focus on development of advanced diagnostic techniques, growing research & development activities, and rising funding by major market players. For instance, in September 2022, The Department of Defense's Kidney Cancer Research Program has granted Weill Cornell Medicine $1 million over three years for research investigating the function of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of kidney cancer, rising product launches by the key market players, growing research & development expenditures by pharmaceutical companies, and increasing funding for research. For instance, in April 2023, The FY23 Defense Appropriations Act allocates funds for the Kidney Cancer Research Program (KCRP), specifically to back high-quality scientific research focused on kidney cancer. The entity responsible for overseeing the forthcoming funding opportunities is the CDMRP, housed within the U.S. Army Medical Research and Development Command (USAMRDC). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising incidences of kidney cancer, growing geriatric population, increasing awareness regarding cancer, surge in research & development expenditure by pharmaceutical companies, rising launch of novel drugs for the treatment of kidney cancer, and growing initiatives by major market players. For instance, in March 2023, Telix has reported further favorable findings from its concluded pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with clear cell renal cell carcinoma (ccRCC).
Segmentation: Kidney Cancer Therapeutics & Diagnostics Market Report 2022 - 2033
Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast by Cancer Type 2023 - 2034 (Revenue USD Bn)
- Papillary Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Urothelial Carcinoma/Transitional Cell Carcinoma
- Others
- Renal Sarcoma
- Collecting Duct Renal Cell Carcinoma
- Wilms Tumor
Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast by Component 2023 - 2034 (Revenue USD Bn)
Drugs
- Therapeutic Class
- Targeted Therapy
- Immunotherapy
- Others
- Pharmacologic Class
- Angiogenesis Inhibitors
- Monoclonal Antibodies
- mTOR Inhibitors
- Cytokine Immunotherapy (IL-2)
Diagnostics
- Biopsy
- Imaging Tests
- Blood Tests
- Others
Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Genomic Laboratories
- Pharmaceutical Labs
- Hospitals
- Others
Kidney Cancer Therapeutics & Diagnostics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Kidney Cancer Therapeutics & Diagnostics Market: Cancer Type Estimates & Trend Analysis
8. Kidney Cancer Therapeutics & Diagnostics Market: Component Estimates & Trend Analysis
9. Kidney Cancer Therapeutics & Diagnostics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Kidney Cancer Therapeutics & Diagnostics Market
12. Europe Global Kidney Cancer Therapeutics & Diagnostics Market
13. Asia Pacific Global Kidney Cancer Therapeutics & Diagnostics Market
14. Latin America Global Kidney Cancer Therapeutics & Diagnostics Market
15. MEA Global Kidney Cancer Therapeutics & Diagnostics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Abbott Laboratories
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche
- Exelixis Inc.
- Bayer AG
- Seattle Genetic
- Merck KGaA (EMD Serono)
- Genentech Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.07 Billion |
| Forecasted Market Value ( USD | $ 11.09 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
